

# Index

- ACP. *See* advance care planning
- activity-based interventions, for dementia  
   exercise therapy, 216–17  
   individual activity programmes, 217
- acute medical settings, residence capacity assessment in, 308–9, 310
- AD. *See* Alzheimer's disease
- Addenbrooke's Cognitive Examination, 41
- ADL. *See*  
   adrenoleukodystrophy
- ADNI study. *See* Alzheimer's Disease Neuroimaging Initiative study
- adrenoleukodystrophy (ADL), 67
- adrenomyeloneuropathy (AMN), 67
- Adults with Incapacity (Scotland) Act 2000, 279, 281
- advance care planning (ACP), 236
- agitation, pain and, 233
- agomelatine, 246
- AIDS dementia complex, 57–8
- alcohol misuse, 92, 101–2  
   acute presentations of, 96–7  
   assessment of, 93–4  
   brain damage related to, 99  
   challenges to recovery from, 95  
   drug interactions with, 98–9  
   drug misuse with, 108  
   epidemiology of, 16, 92–3  
   family and carer support for, 94–5  
   legal and ethical aspects of, 95–6  
   multi-agency working for, 100–1  
   physical presentations of, 97–8  
   psychosocial interventions for, 94, 95  
   screening for, 94  
   self-harm and suicide associated with, 98  
   toxicity associated with, 62
- Alcohol Use Disorders Identification Test (AUDIT), 94
- alcohol withdrawal syndrome, 96–7
- alcohol-related brain damage (ARBD), 99
- alcohol-related dementia, 45
- allocation, for home assessment, 130–1
- ALS. *See* amyotrophic lateral sclerosis
- aluminium toxicity, 60
- Alzheimer's disease (AD). *See also* preclinical AD  
   diagnostic criteria for, 167, 174, 176  
   driving with, 141  
   epidemiology of, 5, 9–10  
   familial, 50  
   neuroimaging in diagnosis of, 173–4, 176, 186–7  
   CT, 174  
   future techniques for, 178  
   MRI, 174–7  
   PET, 177–8  
   SPECT, 177  
   risk factors for, 9–10  
   VaD/VCI compared with, 30–1  
   VaD/VCI mixed with, 24–5, 26  
   young-onset, 43
- Alzheimer's Disease Neuroimaging Initiative (ADNI) study, 166
- aMCI. *See* amnesic mild cognitive impairment
- AMCP. *See* Approved Mental Capacity Professional
- AMN. *See* adrenomyeloneuropathy
- amnesic mild cognitive impairment (aMCI), 161, 162
- amphetamines, misuse of, 106, 108
- amyloid- $\beta$ , in AD  
   at different disease stages, 166  
   measurement of, 164–5, 178  
   pathophysiology, 162–3  
   predictive accuracy of, 165–6
- amyotrophic lateral sclerosis (ALS), 52
- analytical epidemiology, 5–6
- animal-assisted therapy, 216
- anoxic brain injury, 63
- antibiotics, in advanced dementia, 233–4
- anticholinergic medications, toxicity associated with, 60–1
- antidepressants  
   for depression in PD, 116–18  
   for late-life depression  
     age-related physiological changes affecting, 244  
     combination and augmentation therapy, 246–7  
     dementia with, 249  
     monotherapy, 245–6  
     relapse prevention, 247  
     response time for, 246  
   mania induced by, 79  
   toxicity associated with, 60–1  
   for young-onset dementia, 47
- antipsychotic agents  
   for bipolar disorder, 86  
   for delirium, 261–2  
   DLB with sensitivity to, 45  
   for late-life depression, 246–7  
   for PD psychosis, 121  
   toxicity associated with, 60  
   for young-onset dementia, 47

- anxiety-related disorders  
 bipolar disorder comorbidity  
   with, 83  
 epidemiology of, 15  
 in PD, 119–20  
 apathy, in PD, 118–19  
 Approved Mental Capacity  
   Professional  
   (AMCP), 301  
 ARBD. *See* alcohol-related  
   brain damage  
 aripiprazole, 246–7  
 aromatherapy, 215–16  
 arsenic poisoning, 59  
 art therapy, 214  
 artificial nutrition, in advanced  
   dementia, 234  
 ataxias, 52  
 AUDIT. *See* Alcohol Use  
   Disorders Identification  
   Test  
 autoimmune disorders. *See*  
   inflammatory and  
   autoimmune disorders  
 autoimmune limbic  
   encephalitis, 69  
 autosomal inheritance, of  
   dementia, 72
- B (by her litigation friend, the  
 Official Solicitor)  
 v A Local Authority*  
 [2019], 312–13
- barrier analysis  
 in care homes, 266, 275  
 Bridgend mental health  
   service for older adults,  
   267–9  
 development of liaison  
   service to care home  
   sector, 271, 275  
 results of review process,  
   272–4, 275  
 review process, 272  
 in healthcare, 270–1  
 technique of, 269–70  
 bathroom assessment, 135  
 bedroom assessment, 135  
 bedside tests, of frontal lobe  
   function, 41, 42  
 behavioural and psychological  
   symptoms of dementia  
   (BPSD), 11, 224  
 behavioural variant FTD, 44  
 Behçet disease, 70–1  
 benzodiazepines  
   for alcohol withdrawal  
   syndrome, 96–7  
   for delirium, 262  
   misuse of, 106–7,  
   110–11, 113  
 Binswanger's disease, 53  
 biomarkers  
   for DLB diagnosis, 181–2  
   of preclinical AD, 161–2, 169  
   detection and  
   measurement of,  
   164–5, 178  
   diagnostic criteria using,  
   167–8  
   at different disease  
   stages, 166  
   ethical implications of,  
   168–9  
   FDG PET, 167  
   further questions for, 170  
   limitations of, 168  
   pathophysiology of AD  
   and, 162–3  
   predictive accuracy of,  
   165–6  
   terminology used in,  
   161, 162  
 bipolar disorder, 13–14, 80. *See*  
   also mania in late life  
 Bournewood gap, 294  
 bovine spongiform  
   encephalopathy, 55  
 BPSD. *See* behavioural and  
   psychological  
   symptoms of dementia  
 brain damage. *See also* head  
   trauma and diffuse  
   brain damage  
   alcohol-related, 99  
 brain tumours, 68–9  
 Bridgend mental health  
   service for older  
   adults, 267  
   dementia care training  
   package for, 269  
   dementia care training team  
   in, 267–9  
   liaison service to  
   development of, 271, 275  
   results of review process,  
   272–4, 275  
   review process, 272  
 CAA. *See* cerebral amyloid  
   (congophilic)  
   angiopathy  
 CADASIL. *See* cerebral  
   autosomal dominant  
   arteriopathy with  
   subcortical infarcts and  
   leukoencephalopathy  
 CAGE questionnaire, 94,  
   109, 110  
 CamPaIGN study, 122  
 'Can Gerry Robinson fix  
   Dementia Care  
   Homes?', 266  
 Canadian Driving Research  
   Initiative for Vehicular  
   Safety in the Elderly  
   (CanDRIVE), 145  
 cannabis misuse, 106, 108, 111  
 capacity. *See* mental capacity;  
   residence capacity  
 carbamazepine, 86  
 carbon monoxide  
   poisoning, 63  
 cardiopulmonary resuscitation  
   (CPR), in advanced  
   dementia, 235  
 care coordination, in palliative  
   care for dementia,  
   229–30  
 care homes  
   barrier analysis in, 266, 275  
   Bridgend mental health  
   service for older adults,  
   267–9  
   development of liaison  
   service to care home  
   sector, 271, 275  
   results of review process,  
   272–4, 275  
   review process, 272  
   for dementia, 228–9  
   DoL 'acid test' in, 298  
 carer reports, driving risk  
   assessment with, 140  
 carer-focused  
   interventions, 218  
 carers  
   alcohol misuse and, 94–5  
   assessment of, 136  
   co-working role for, 207, 208  
   interview of, 133  
 case-control studies, 7–8  
 causative nexus, capacity and,  
   307–8, 313–14  
 CBT. *See* cognitive-behavioural  
   therapy  
 CC v KK and STCC [2012],  
   309–11

- cerebral amyloid (congoophilic) angiopathy (CAA), 29, 53
- cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 28–9, 53–4
- cerebral hypoxia, 63
- cerebral lipidoses – adult variant, 68
- cerebral toxocariasis, 57
- cerebral tumours, 68–9
- cerebrospinal fluid (CSF), AD biomarkers in, 164–5, 169
- at different disease stages, 166
- further questions for, 170
- limitations of, 168
- predictive accuracy of, 165–6
- cerebrovascular disease. *See* vascular dementia/vascular cognitive impairment
- CFAS. *See* Cognitive Function and Ageing Studies
- ChEIs. *See* cholinesterase inhibitors
- ‘Cheshire West’ judgment, 294–6
- residence capacity and, 308
- cholinesterase inhibitors (ChEIs), for VaD/VCI, 31–3
- chronic kidney disease, lithium use and, 85
- chronic subdural haematoma, 64
- citalopram, for late-life depression, 245, 246–7
- civil detention, 282
- clinician role in, 282
- discharge from, 288
- other routes to, 290
- RC/RMO role in, 288
- tribunal role in, 288–90
- emergency, 283, 284–5
- for mental disorder, 282
- short-term and longer-term detention, 283–6
- statutory criteria for, 282, 284–5
- CJD. *See* Creutzfeldt–Jakob disease
- clozapine, 121
- CNS vasculitis, 70
- cocaine misuse, 106, 107–8
- coeliac disease, 70
- cognition, substance misuse impacts on, 111
- Cognitive Function and Ageing Studies (CFAS), 8–9, 29
- cognitive impairment. *See also* dementia
- alcohol misuse and, 95–6
- bipolar disorder comorbidity with, 83
- depression causing, 250
- in PD, 45, 121–3
- cognitive interventions, 217–18
- cognitive reserve, 162–3
- cognitive testing. *See* neuropsychological testing
- cognitive-behavioural therapy (CBT)
- for bipolar disorder, 87
- for late-life depression, 247–8
- cognitive-friendly services for delirium
- definition of, 256–7
- discharge planning and post-hospitalization management, 262
- experience, education and action in, 257–8
- improved detection in, 260
- key elements for improved care, 262, 263
- multicomponent non-pharmacological management, 260–1
- pharmacological management, 261–2
- primary care practitioners role in, 260
- risk factor minimization and prevention in, 259–60
- cohort studies, 8
- collaborative care, for late-life depression, 247
- community engagement, in dementia care, 205–6
- community reinforcement approach (CRA), 101
- community treatment orders (CTOs), 281
- compulsory mental health treatment, 279–82, 286, 289
- without consent, 286–7
- second opinion safeguards in, 287
- urgent treatment, 287–8
- computerized tomography (CT)
- AD, 174
- DLB, 182
- other neuroimaging techniques compared with, 175
- VaD/VCI, 26, 28–9, 179
- confidentiality, driving with dementia and, 142, 144
- congoophilic angiopathy, 29, 53
- consent
- capacity for, 306–7
- for home assessment, 131
- treatment without, 286–7
- consent to treatment
- provisions, 286–8, 289
- constipation, in advanced dementia, 231
- constitutive account, 320
- contingent account, 320
- Coroners and Justice Act 2009, 298–9
- cortical disconnection syndrome, 53
- corticobasal degeneration, 51
- co-working, in dementia care, 207, 208
- CPR. *See* cardiopulmonary resuscitation
- CRA. *See* community reinforcement approach
- creative interventions, for dementia
- art therapy, 214
- music/dance therapy, 214–15
- reminiscence therapy, 214
- Creutzfeldt–Jakob disease (CJD)
- familial, 55
- iatrogenic, 54
- neuroimaging in diagnosis of, 184, 187
- sporadic, 54
- variant, 55, 184
- cross-sectional surveys, 7
- CRPD. *See* United Nations Convention on the Rights of Persons with Disabilities
- CSF. *See* cerebrospinal fluid

- CT. *See* computerized tomography
- CTOs. *See* community treatment orders
- cultural shifts, in dementia care, 210
- DA. *See* dopamine agonists
- dance therapy, 214–15
- DAST. *See* Drug Abuse Screening Test
- DaTScan, 173–4  
   in DLB, 182–3
- DAWS. *See* dopamine agonist withdrawal
- DDS. *See* dopamine dysregulation syndrome
- DDSA. *See* Dementia Drivers Screening Assessment
- death. *See* mortality
- decision-making, shared, 207
- DEEP. *See* Dementia Engagement and Empowerment Project
- degenerative causes of dementia, 50, 51  
   ALS/MND, 52  
   ataxias, 52  
   corticobasal degeneration, 51  
   familial AD, 50  
   FTDs, 51  
   Huntington's disease, 52  
   multiple system atrophy, 51–2  
   polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, 53  
   pure hippocampal sclerosis (ageing subtype), 50–1
- delayed post-anoxic encephalopathy, 63
- delirium, 254. *See also* cognitive-friendly services for delirium
- dementia and, 14–15
- DSM-5 criteria, 255, 256
- epidemiology of, 14–15, 254–5
- as key healthcare challenge, 254–5
- nosology of, 255–6
- in PD, 123
- residence capacity  
   assessment and, 308–9, 310, 313
- delirium tremens, 97
- dementia. *See also* driving with dementia;  
   epidemiology;  
   neuroimaging in dementia; palliative care in dementia; self-management in dementia; young-onset dementias; *specific dementias*  
   alcohol-related, 99  
   clinico-philosophical case discussion of, 317–18, 325  
   case vignette of SEA view in practice, 320–4  
   discussion, 324–5  
   interventions and, 323–4  
   SEA view of person, 318–20  
   therapeutic engagement and, 324
- death and, 12
- definition of, 38
- delirium and, 14–15
- delivery of diagnosis of, 207
- depression with, 8, 12  
   treatment of, 249–50  
   VaD/VCL, 32, 33  
   young-onset, 47
- inadequate treatment of, 224–6
- inappropriate interventions in, 224–6
- 'living well' with, 191–2
- mixed or multiple pathologies in, 24–5, 26, 29
- MMSE in assessment of  
   for diagnosis, 151, 152  
   for early dementia, 151–3  
   implementation of, 154–7  
   for MCI detection, 152, 153  
   for prediction of future dementia, 154  
   for screening, 149, 150
- morbidity and mortality in advanced, 224–6
- PCC in, 202, 210–11, 317–18, 324–5
- challenges to practice of, 209–10
- definition of recovery and, 202–3
- RFP key aspects for, 205–9
- RFP parallels with, 203–5
- in PD, 45, 121–3
- predictors of death in, 230–1
- prisoners with, 237
- psychosocial interventions in, 213–14, 219  
   activity-based, 216–17  
   carer-focused, 218  
   creative, 214–15  
   environmental, 218  
   psychological, 217–18  
   sensory, 215–16
- rare causes of, 50  
   autosomal inheritance of, 72  
   degenerative, 50–3  
   endogenous, 58, 64–71  
   exogenous, 58–64  
   human prion diseases, 54–6  
   infectious, 56–8  
   psychiatrist's role in, 71–4, 73  
   vascular, 53–4
- risk factors for, 9–10
- screening for, MMSE, 149, 150, 154–6, 157
- dementia care training, 267–9
- Dementia Drivers Screening Assessment (DDSA), 146
- Dementia Engagement and Empowerment Project (DEEP), 210
- dementia-friendly communities, 205–6
- dementia pugilistica, 63
- dementia with Lewy bodies (DLB)  
   diagnostic criteria for, 181–2  
   driving with, 141  
   epidemiology of, 11  
   neuroimaging in diagnosis of, 173–4, 180, 181–2, 187  
   CT, 182  
   functional neuroimaging, 182–3  
   young-onset, 45

- depression. *See also* late-life depression  
 dementia with, 8, 12  
 treatment of, 249–50  
 VaD/VCI, 32, 33  
 young-onset, 47  
 epidemiology of, 13  
 in PD, 116–18  
 substance misuse with, 93–4, 98, 106–7
- depressive pseudodementia, 186, 250
- deprivation of liberty (DoL), 293, 303  
 ‘acid test’ for, 294, 296–7  
 in general hospitals, 298–9  
 in psychiatric settings, 297  
 in social care settings, 298  
 background to concept of, 293–4  
 Liberty Protection  
 Safeguards, 293  
 amendments to, 300–3  
 background to, 299–300  
 Supreme Court Judgment in P and Q and P in Cheshire West, 294–6
- Deprivation of Liberty Safeguards (DoLS), 293–4, 297, 299–300
- descriptive epidemiology, 5–6
- descriptive studies, 6–7
- detention. *See* civil detention
- Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition (DSM-5)
- bipolar disorder  
 classification in, 78–9  
 classification of major cognitive disorder and minor cognitive disorders in, 154–5  
 delirium criteria in, 255, 256
- dialysis dementia syndrome, 60
- diffuse brain damage. *See* head trauma and diffuse brain damage
- diffuse subcortical SVD, 27–30, 53
- discharge from civil detention, 288  
 other routes to, 290  
 RC/RMO role in, 288  
 tribunal role in, 288–90
- discharge planning, 262
- disinhibition syndrome, 79–80
- distress behaviours, 224
- disulfiram, 99
- DLB. *See* dementia with Lewy bodies
- DoL. *See* deprivation of liberty
- doll therapy, 217
- DoLS. *See* Deprivation of Liberty Safeguards
- donepezil, 31–3, 46–7
- dopamine agonist withdrawal (DAWS), 123
- dopamine agonists (DA), ICDs with, 123
- dopamine dysregulation syndrome (DDS), 123–4
- Down’s syndrome, 185
- Driver and Vehicle Licensing Agency (DVLA), 139  
 driving with dementia guidance, 143–4
- driving with dementia, 139, 146–7  
 ability tests for  
 in-office testing, 145–6  
 on-road testing, 144  
 assessment of risk in, 139  
 carer reports, 140  
 clinical presentation, 141  
 collateral information, 140  
 comorbidities, 141  
 self-reports, 140
- legislation on  
 DVLA medical guidance, 143–4  
 physician reporting requirements, 142  
 retirement from, 141  
 available alternative transport impact on, 142  
 behaviour modification, 141  
 cessation, 142
- Drug Abuse Screening Test (DAST), 109
- drug misuse, 105–6, 113  
 benzodiazepines and hypnotics, 106–7  
 cannabis, stimulants, and hallucinogens, 108  
 diagnostic challenges of, 109, 110  
 epidemiology of, 16, 106, 107  
 impacts of, 109, 110  
 cognition, 111  
 mental health, 110–11  
 physical health, 111  
 inappropriate and over-the-counter medications, 108  
 opioids and cocaine, 107–8  
 polysubstance, 108  
 risk factors for, 106, 107  
 toxicity associated with, 62  
 treatment and outcomes of, 111–12  
 benzodiazepines, 113  
 opioids, 112–13
- DSM-5. *See* *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition
- dual syndrome hypothesis, 122
- DVLA. *See* Driver and Vehicle Licensing Agency
- early-onset dementia. *See* young-onset dementias
- eating disorders, 15
- ECA study. *See* Epidemiologic Catchment Area study
- ECHR. *See* European Convention on Human Rights and Fundamental Freedoms
- electroconvulsive therapy (ECT)  
 for bipolar disorder, 86–7  
 compulsory treatment with, 287–8  
 for late-life depression, 248–9
- emergency detention, 283, 284–5
- endocrine disorders, dementia caused by, 65  
 diabetes mellitus, 66  
 hyperparathyroidism, 64–5  
 hypoparathyroidism/hypocalcaemia, 65  
 hypothyroidism or raised thyroxine, 64
- end-of-life care. *See* palliative care
- England and Wales  
 civil detention in, 282–6, 288–90  
 consent to treatment provisions in, 286–8, 289

- mental health laws of, 279–82, 290–1
- environmental  
   interventions, 218
- environments, cognitive-friendly. *See* cognitive-friendly services
- Epidemiologic Catchment Area (ECA) study, 15
- epidemiology, 5  
   conclusions on mental health in old age, 17
- definitions of terms used in, 5–6
- of dementia  
   AD, 5, 9–10  
   BPSD, 11  
   comorbid disease, 12  
   incidence, 7, 8–9  
   Lewy body dementia, 11  
   mortality, 12  
   PDD, 121–3  
   prevalence, 6–7, 8–9, 39, 50, 73  
   vascular dementia, 10–11, 24–5, 31  
   young-onset, 39
- of functional illnesses  
   anxiety-related disorders, 15  
   bipolar disorder, 13–14, 80  
   delirium, 14–15, 254–5  
   depression, 13  
   eating disorders, 15  
   late-onset schizophrenia, 14  
   personality disorders, 15–16  
   substance misuse, 16, 92–3, 106, 107
- of mania in late life, 80
- observational study designs used in, 6–8
- of suicide in elderly, 16, 17, 18
- escitalopram, 245
- ethical aspects  
   of AD biomarker positivity, 168–9  
   of alcohol misuse, 95–6
- European Convention on Human Rights and Fundamental Freedoms (ECHR), 281, 282, 293–4
- exercise therapy, 216–17
- falls  
   alcohol misuse and, 97–8  
   environmental risk factors for, 134
- familial AD, 50
- familial CJD, 55
- family members  
   co-working role for, 207, 208  
   interview of, 133, 136
- family support  
   for alcohol misuse, 94–5  
   assessment of, 136
- fatal familial insomnia, 55
- FDG PET. *See* fludeoxyglucose positron emission tomography
- fever, in advanced dementia, 233–4
- fludeoxyglucose positron emission tomography (FDG PET), dementia diagnosis with, 173–4
- AD, 177–8  
   AD biomarkers, 167
- folate deficiency, 62
- Friedreich's ataxia, 52
- frontal lobe dysfunction  
   bedside tests of, 41, 42  
   symptoms of, 44
- frontotemporal  
   dementia (FTD)  
   as degenerative cause of dementia, 51  
   driving with, 141  
   neuroimaging in diagnosis of, 173–4, 183–4, 187  
   young-onset, 43–4  
   behavioural form, 44  
   language forms, 45
- functional approach, to residence capacity assessment, 309–11
- functional neuroimaging. *See also* fludeoxyglucose positron emission tomography; positron emission tomography; single-photon emission computed tomography  
   in AD, 177–8  
   in DLB, 182–3  
   in VaD/VCI, 179–80
- FX, Re* [2017], 311
- galantamine, 31–3, 46–7
- garden assessment, 135
- gastrointestinal system,  
   alcohol-related damage of, 97–8
- Gaucher disease, 68
- general hospitals, DoL 'acid test' in, 298–9
- General Medical Council (GMC), guidance on confidentiality and driving with dementia, 144
- general practitioner (GP),  
   home assessment referral by, 130–1
- genetics, rare causes of dementia, 72
- Gerstmann–Straussler–Scheinker disease, 55–6
- glucocorticosteroid dementia syndrome, 61
- GMC. *See* General Medical Council
- GP. *See* general practitioner
- haemochromatosis, 67
- Hallervorden–Spatz syndrome.  
   *See* pantothenate kinase-associated neurodegeneration
- hallucinations, in PD, 120–1
- hallucinogen misuse, 106, 108
- haloperidol, 261–2
- head trauma and diffuse brain damage, dementia caused by, 59  
   acute head injury, 63  
   anoxic brain injury/delayed post-anoxic encephalopathy, 63
- chronic subdural haematoma, 64
- dementia pugilistica, 63
- normal-pressure hydrocephalus, 63–4  
   in soccer players, 63
- Heart of England NHS Foundation Trust v JB* [2014], 306–7
- heavy metal toxicity, 58–60
- Heidegger, Martin, 319–20
- Helping Older People Experience Success (HOPES), 87–8
- hepatic encephalopathy, 66
- heroin misuse, 106, 107–8
- herpes viruses, 57



- HIV-related dementia, 57–8  
 holding powers, 283  
 home assessment, 129, 137  
   advantages and  
     disadvantages of,  
     129, 130  
 bathroom and bedroom, 135  
 commencement of  
   neighbourhood and home  
   exterior  
   observation, 133  
   start of interview, 133  
 corroborative history  
   after, 136  
 garden, 135  
 general observations, 133–4  
 home help and family  
   support, 136  
 kitchen, 135  
 living room, 134–5  
 medications, 135–6  
 potential problems identified  
   by, 130  
 preparation for  
   equipment, 132  
   identification of risks and  
   safety issues for staff,  
   131–2  
   initial contact, 131  
   referral and allocation,  
   130–1  
 home help, assessment of, 136  
 home-based palliative care, for  
   dementia, 229  
 hope, maintenance of, 209  
 HOPES. *See* Helping Older  
   People Experience  
   Success  
 hospice care, for dementia,  
   228–9  
 hospitals, cognitive-friendly.  
   *See* cognitive-friendly  
   services  
 human prion diseases, 54  
   familial CJD, 55  
   fatal familial insomnia, 55  
   Gerstmann–Straussler–  
   Scheinker disease, 55–6  
   iatrogenic CJD, 54  
   sporadic CJD, 54  
   variant CJD, 55, 184  
 human rights law, 281, 282  
 human spongiform  
   encephalopathy, 55  
 Hume, David, 318  
 Huntington's disease  
   as degenerative cause of  
   dementia, 52  
   neuroimaging in diagnosis  
   of, 184, 187  
   young-onset dementia  
   in, 45–6  
 hydration, in advanced  
   dementia, 234  
 hyperparathyroidism, 64–5  
 hypertension, 31, 33  
 hypnotic misuse, 106–7  
 hypocalcaemia, 65  
 hypomania in late life. *See*  
   mania in late life  
 hypoparathyroidism, 65  
 hypothyroidism, 64  
 iatrogenic CJD, 54  
 ICD-11, bipolar disorder  
   classification in, 78–9  
 ICDs. *See* impulse control  
   disorders  
 identity issues, in RFP and PCC  
   for dementia, 205  
 impulse control disorders  
   (ICDs), in PD, 123  
 inappropriate medications,  
   misuse of, 108  
 incapacity laws, 279–82, 306  
 incidence, 5, 6  
   of dementia, 7, 8–9  
 inclusion, in dementia care,  
   205–6  
 incontinence, in advanced  
   dementia, 231  
 individual activity  
   programmes, for  
   dementia, 217  
 infection, in advanced  
   dementia, 233–4  
 infectious causes of  
   dementia, 56  
   cerebral toxocariasis, 57  
   HIV-related dementia and  
   AIDS dementia  
   complex, 57–8  
   Lyme disease, 56  
   neurocysticercosis, 57  
   neurosyphilis, 56–7  
   subacute sclerosing  
   panencephalitis, 58  
   viral encephalitis, 57  
 inflammatory and  
   autoimmune disorders,  
   dementia caused by,  
   65, 69  
 autoimmune limbic  
   encephalitis, 69  
 Behçet disease, 70–1  
 coeliac disease, 70  
 MS, 69  
 neurosarcoidosis, 70  
 Sjögren syndrome, 71  
 systemic and CNS  
   vasculitis, 70  
 systemic lupus  
   erythematosus, 71  
 inhalants, misuse of, 106, 108  
 initial contact, for home  
   assessment, 131  
 in-office testing, of driving  
   ability, 145  
   UK, 146  
   USA and Canada, 145  
 Integrated Palliative care  
   Outcome Scale for  
   Dementia (IPOS-Dem),  
   230–1  
 intellectual disability, dementia  
   in people with, 185  
 interferon, toxicity associated  
   with, 61  
 International Consensus  
   Criteria, for DLB  
   diagnosis, 181–2  
 investigations  
   mania in late life, 82  
   VaD/VCI, 32  
   young-onset  
   dementias, 41–2  
 IPOS-Dem. *See* Integrated  
   Palliative care Outcome  
   Scale for Dementia  
 ischaemic stroke, VaD/VCI  
   after, 26–7  
 kitchen assessment, 135  
 Korsakoff's psychosis, 97  
 lacunar stroke, VaD/VCI after,  
   27, 28  
 late-life depression, 243, 250  
   dementia and, 249–50  
   diagnosis and aetiology of,  
   243–4  
   epidemiology of, 13  
   evidence base for treatment  
   of, 245  
   neurostimulation for,  
   248–9  
   non-pharmacological  
   therapies for, 247–8

- pharmacological  
 treatment of  
 age-related physiological  
 changes affecting, 244  
 combination and  
 augmentation therapy,  
 246–7  
 dementia and, 249  
 monotherapy, 245–6  
 relapse prevention, 247  
 response time for, 246  
 late-onset schizophrenia, 14  
 lead poisoning, 58–9  
 legal aspects, of alcohol  
 misuse, 95–6  
 legislation  
 on driving with dementia  
 DVLA medical guidance,  
 143–4  
 physician reporting  
 requirements, 142  
 UK mental health laws, 279,  
 290–1  
 civil detention, 282–6  
 compulsory mental health  
 treatment in hospital,  
 279–82, 286–8, 289  
 discharge from civil  
 detention, 288–90  
 overview of, 279–82  
 Lewy body dementia. *See*  
 dementia with Lewy  
 bodies  
 Liberty Protection Safeguards  
 (LPS), 293  
 amendments to  
 advocacy, 302  
 age, 300  
 AMCP role, 301  
 arrangements, 301  
 authorization criteria, 301  
 authorization effect and  
 duration, 302  
 care home  
 arrangements, 302  
 consultation, 301  
 legal appeals, 302  
 MHA/LPS interface, 303  
 pre-authorization  
 review, 301  
 renewals and reviews, 302  
 statutory definition, 300  
 background to, 299–300  
 licence. *See* driving with  
 dementia  
 light therapy, 215  
 likelihood ratios, 30  
 lithium  
 for bipolar disorder, 85  
 for late-life depression,  
 246  
 as rare cause of dementia,  
 60  
 liver disease, substance misuse  
 and, 111  
 living room assessment, 134–5  
 ‘living well’ with dementia,  
 191–2  
 Locke, John, 318  
*London Borough of Hackney*  
*v SJF (through her*  
*Litigation Friend the*  
*Official Solicitor), JFF*  
 [2019], 313–14  
 longer-term detention, 283–6  
 LPS. *See* Liberty Protection  
 Safeguards  
 LSD, 108  
 Lyme disease, 56  
 magnetic resonance imaging  
 (MRI), 178  
 AD, 174–7  
 CJD, 184  
 other neuroimaging  
 techniques compared  
 with, 175  
 VaD/VCI, 26, 28–9, 179  
 major cognitive disorder,  
 DSM-5 classification of,  
 154–5  
 major depressive disorder,  
 epidemiology of, 13  
 major stroke, VaD/VCI  
 after, 26–7  
 manganese toxicity, 59  
 mania in late life, 78, 88  
 aetiology of, 81  
 burdens of  
 economic, 80–1  
 morbidity and  
 mortality, 81  
 suicide, 81  
 classification of, 78–9  
 course of, 88  
 diagnosis and assessment  
 of, 81–3  
 differential, 82  
 investigations, 82  
 screening instruments, 83  
 epidemiology of, 80  
 management of, 83–4  
 non-pharmacological,  
 86–8  
 pharmacological, 84–6  
 prevention of, 88  
 psychiatric comorbidity with  
 anxiety disorders and  
 substance misuse, 83  
 cognitive impairment, 83  
 terms specific to, 79–80  
 MAOIs. *See* monoamine  
 oxidase inhibitors  
 MCA. *See* Mental Capacity Act  
 2005  
 MCI. *See* mild cognitive  
 impairment  
 McKhann criteria, 167,  
 174, 176  
 medications  
 home assessment of,  
 135–6  
 toxicity associated with,  
 60–1  
 memantine, 31–3, 122  
 for young-onset  
 dementia, 46–7  
 mental capacity  
 alcohol misuse and, 95–6  
 UK laws on, 279–82, 306  
 Mental Capacity Act 2005  
 (MCA), 95–6, 279, 281  
 residence capacity and, 306  
 Mental Capacity (Northern  
 Ireland) Act 2016, 280,  
 281, 286, 290–1  
 Mental Capacity (Amendment)  
 Act 2019, 299  
 mental disorder, MHA  
 definition of, 282  
 Mental Health Act 1983  
 (MHA), 95–6, 279, 281,  
 282, 283, 284–5, 287–8,  
 289, 290–1  
 DoL and, 294, 297, 303  
 Mental Health (Care and  
 Treatment) (Scotland)  
 Act 2003 (MHCTA),  
 279, 281, 284–5, 289  
 mental health laws, 279, 290–1  
 civil detention, 282–6  
 compulsory mental health  
 treatment in hospital,  
 279–82, 286–8, 289  
 discharge from civil  
 detention, 288–90  
 overview of, 279–82  
 Mental Health Toolkit, 266



- mental illness, 17. *See also specific mental illnesses*  
 dementia with, 12  
 substance misuse with, 110–11  
 VaD/VCI with, 32
- Mental (Northern Ireland) Order 1986 (NI Order), 279, 280, 281, 284–5, 289
- mercury poisoning, 59
- Merleau-Ponty, Maurice, 320
- metabolic disorders, dementia  
 caused by, 65  
 adrenoleukodystrophy and adrenomyeloneuropathy, 67  
 cerebral lipidoses – adult variant, 68  
 haemochromatosis, 67  
 metachromatic leukodystrophy, 67  
 neuroacanthocytosis, 68  
 PKAN, 67–8  
 Wilson's disease, 66–7
- metachromatic leukodystrophy, 67
- MHA. *See* Mental Health Act 1983
- MHCTA. *See* Mental Health (Care and Treatment) (Scotland) Act 2003
- microinfarcts, 27
- mild cognitive impairment (MCI)  
 cerebrovascular disease with, 24  
 CSF biomarkers for AD development in, 165–6  
 definition of, 161, 162  
 driving with, 141, 144  
 MMSE in assessment of for detection of MCI, 152, 153  
 implementation of, 154–7  
 for prediction of future dementia in MCI, 154  
 neuroimaging in, 173–4, 175, 185  
 in PD, 121–3  
 screening for, 149, 150, 154–6, 157
- Mini-Mental State Examination (MMSE), 32, 41  
 applications of, 150
- clinical implementation of, 154–7  
 dementia screening with, 149, 150, 154–6, 157  
 as diagnostic test for dementia, 151, 152  
 early dementia diagnostic validity of, 151–3  
 limitations of, 154  
 MCI detection with, 152, 153  
 prediction of future dementia with, 154  
 structure and validation of, 150
- minor cognitive disorders, DSM-5  
 classification of, 154–5
- mirtazapine, for late-life depression, 245, 249
- MMSE. *See* Mini-Mental State Examination
- MND. *See* motor neuron disease
- MOCA. *See* Montreal Cognitive Assessment
- monoamine oxidase inhibitors (MAOIs)  
 for depression in PD, 118  
 toxicity associated with, 61
- Montreal Cognitive Assessment (MOCA), 32
- mortality  
 in advanced dementia, 224–6  
 predictors of, 230–1  
 alcohol misuse, 92–3  
 bipolar disorder, 81  
 dementia and, 12  
 drug misuse, 109, 110
- motor neurone disease (MND), 52
- MRI. *See* magnetic resonance imaging
- MS. *See* multiple sclerosis
- multi-agency working, for alcohol misuse, 100–1
- multiple sclerosis (MS), 69
- multiple system atrophy, 51–2
- multisensory stimulation, 216
- music therapy, 214–15
- Namaste Care, 228–9
- Nasu–Hakola disease, 53
- National Institute for Health and Clinical Excellence (NICE)  
 bipolar disorder treatment recommendations, 84  
 delirium treatment recommendations, 261–2  
 dementia treatment recommendations, 31–3, 46–7  
 staff training guidance of, 267–8  
 young-onset dementia recommendations, 48
- National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS–ADRDA), AD diagnostic criteria of, 167, 174, 176
- National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS–AIREN), VaD diagnostic criteria of, 178, 179
- National Institute on Aging and the Alzheimer's Association (NIA–AA), AD diagnostic criteria of, 167–8
- needs-driven behaviours, 224
- neighbourhood, assessment of, 133
- neoplasm, dementia caused by, 65, 68–9
- neuroacanthocytosis, 68
- neurocysticercosis, 57
- neurodegeneration, in AD, 162–3  
 biomarkers of, 164–5  
 neurofibrillary tangles, in AD, 162–3  
 biomarkers of, 164–5

- neurofilament light chain (NfL), 164  
 neuroimaging in dementia, 173–4, 186  
 AD, 173–8, 186–7  
 AD biomarkers, 164–5, 167, 178  
 CJD, 184, 187  
 depressive  
 pseudodementia, 186  
 DLB, 173–4, 180–3, 187  
 FTD, 173–4, 183–4, 187  
 Huntington's disease, 184, 187  
 MCI, 173–4, 175, 185  
 in people with intellectual disability, 185  
 progressive supranuclear palsy, 184  
 recommendations for, 187–8  
 technique comparison, 175  
 VaD/VCI, 26–9, 32, 178–80, 187  
 young-onset dementias, 41–2, 185–6  
 neuropsychological testing  
 VaD/VCI, 32  
 young-onset dementias, 41, 42  
 neurosarcoidosis, 70  
 neurostimulation, for late-life depression, 248–9  
 neurosyphilis, 56–7  
 NfL. *See* neurofilament light chain  
 NI Order. *See* Mental (Northern Ireland) Order 1986  
 NIA-AA. *See* National Institute on Aging and the Alzheimer's Association  
 niacin deficiency, 62  
 NICE. *See* National Institute for Health and Clinical Excellence  
 Niemann–Pick disease, 68  
 NINCDS-ADRDA. *See* National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association  
 NINDS-AIREN. *See* National Institute of Neurological Disorders and Stroke and Association Internationale pour le Recherché et l'Enseignement en Neurosciences  
 NM-ASSIST, 109  
 non-maleficence, AD  
 biomarker  
 positivity and, 168–9  
 non-tropical sprue, 70  
 normal-pressure  
 hydrocephalus, 63–4  
 Northern Ireland  
 civil detention in, 282–6, 288–90  
 consent to treatment  
 provisions in, 286–8, 289  
 mental health laws of, 279–82, 290–1  
 nortriptyline, for late-life depression, 246  
 nutrition, in advanced dementia, 234  
 observational studies, 5, 6  
 case-control studies, 7–8  
 cohort studies, 8  
 cross-sectional surveys, 7  
 descriptive studies, 6–7  
 ocular biomarkers, of AD, 165  
 odds ratio, 7–8  
 olanzapine, 86, 246–7  
 on-road testing, 144  
 opioid misuse, 106, 107–8  
 polysubstance  
 misuse with, 108  
 treatment and  
 outcomes of, 112–13  
 organ failure, dementia  
 caused by, 65  
 hepatic encephalopathy, 66  
 renal encephalopathy, 66  
 organophosphate exposure, 60  
 Ottawa Driving and Dementia Toolkit, 145  
 over-the-counter medication  
 misuse, 108  
 pain, in advanced dementia, 231–3  
 palliative care in  
 dementia, 223, 236–7  
 ACP in, 236  
 artificial nutrition  
 and hydration in, 234  
 components, domains, and key factors of, 227–8  
 definition of, 223  
 effectiveness of, 226, 228–30  
 infection and fever  
 considerations, 233–4  
 need for improvement  
 of, 224–6, 236–7  
 pain considerations, 231–3  
 physical health  
 considerations, 231  
 prediction of  
 death in, 230–1  
 resuscitation in, 235  
 spectrum of, 224  
 spiritual and religious  
 needs in, 235–6  
 symptoms to address in, 224–6  
 Palliative Excellence in Alzheimer Care Efforts (PEACE), 226  
 pantothenate kinase-associated neurodegeneration (PKAN), 67–8  
 paraneoplastic disorder, 65, 68–9  
 Parfit, Derek, 318  
 Parkinson's disease (PD), neuropsychiatric symptoms  
 of, 116, 117, 124  
 anxiety, 119–20  
 apathy, 118–19  
 cognitive impairment, 45, 121–3  
 delirium, 123  
 depression, 116–18  
 psychosis, 120–1  
 treatment related  
 disorders, 123–4  
 Parkinson's disease  
 dementia (PDD), 45, 121–3  
 PC & NC v City of York Council [2013], 307–8  
 PCC. *See* person-centred care  
 PD. *See* Parkinson's disease

- PDD. *See* Parkinson's disease dementia
- PEACE. *See* Palliative Excellence in Alzheimer Care Efforts
- peer support, in dementia care, 208
- pellagra, 62
- period prevalence, 6
- periventricular white matter lesions, 179
- personality disorders, 15–16
- person-centred care (PCC), 202, 210–11
- challenges to practice of, 209
- cultural shift, 210
- hope maintenance, 209
- transformation of risk management to safety planning, 209–10
- conceptual underpinning to, 317–18, 324–5
- definition of recovery and, 202–3
- RFP key aspects for co-working opportunities, 207, 208
- issues of identity, 205
- need for inclusion, 205–6
- peer support, 208
- self-management empowerment, 208–9
- RFP parallels with, 203–5
- personhood, 206
- clinico-philosophical case discussion of, 317–18, 325
- case vignette of SEA view in practice, 320–4
- discussion, 324–5
- interventions and, 323–4
- SEA view, 318–20
- therapeutic engagement and, 324
- pesticide exposure, 60
- PET. *See* positron emission tomography
- phosphorylated tau (p-tau), in AD, 164, 165–6
- physical health in advanced dementia, 231
- substance misuse impacts on, 111
- physician reporting, of driving with dementia, 142
- pimavanserin, 121
- PKAN. *See* pantothenate kinase-associated neurodegeneration
- plasma, AD biomarkers in, 164
- pneumonia, in advanced dementia, 233–4
- POCD. *See* Post-Operative Cognitive Disorder
- point prevalence, 6
- polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, 53
- polysubstance misuse, 108
- positron emission tomography (PET), 173–4
- AD, 177–8
- AD biomarkers on, 164–5, 167, 178
- DLB, 182–3
- other neuroimaging techniques compared with, 175
- VaD/VCi, 179–80
- post-anoxic encephalopathy, 63
- post-hospitalization management, for delirium, 262
- Post-Operative Cognitive Disorder (POCD), 255–6
- pramipexole, 118
- preclinical AD, 161, 162. *See also* biomarkers
- prescribed medication misuse, 108
- prevalence, 5, 6
- of dementia, 6–7, 8–9, 39, 50, 73
- PRIDE study. *See* Prolonging Remission in the Depressed Elderly study
- primary progressive aphasia, 45
- prion diseases. *See* human prion diseases
- prisoners, with dementia, 237
- problem-solving therapy (PST), 247–8
- prodromal AD, 161, 162
- progressive supranuclear palsy, neuroimaging in diagnosis of, 184
- Prolonging Remission in the Depressed Elderly (PRIDE) study, 248–9
- PST. *See* problem-solving therapy
- psychoeducation, for bipolar disorder, 87
- psychological interventions for dementia
- cognitive interventions, 217–18
- doll therapy, 217
- for late-life depression, 247–8
- dementia with, 249
- psychosis, in PD, 120–1
- psychosocial interventions for alcohol misuse, 94, 95
- for bipolar disorder, 87–8
- for dementia, 213–14, 219
- activity based, 216–17
- carer-focused, 218
- creative, 214–15
- environmental, 218
- psychological, 217–18
- sensory, 215–16
- for late-life depression, 248, 249
- psychotherapy for bipolar disorder, 87
- for young-onset dementias, 47
- p-tau. *See* phosphorylated tau
- public transport, 142
- punch drunk syndrome, 63
- pure hippocampal sclerosis (ageing subtype), 50–1
- quality of life, 17
- quetiapine
- for bipolar disorder, 86
- for delirium, 261–2
- for PD psychosis, 121
- RBs. *See* Responsible Bodies
- RC. *See* responsible clinician
- RDB. *See* Rookwood Driving Battery
- recovery
- definition of, 192, 202–3
- self-management in dementia and, 192–3

- recovery-focused  
 practice (RFP)  
 co-working opportunities,  
 207, 208  
 issues of identity, 205  
 need for inclusion, 205–6  
 PCC parallels with, 203–5  
 peer support, 208  
 self-management  
 empowerment,  
 208–9  
 referral, for home  
 assessment, 130–1  
 relative risk (RR), 8  
 religious needs, in  
 advanced dementia,  
 235–6  
 reminiscence therapy, 214  
 renal encephalopathy, 66  
 renal failure, lithium use  
 and, 85  
 residence capacity, 305, 315  
 assessment of  
 case vignettes, 308–9,  
 310, 314–15  
 causal nexus in, 313–14  
 information necessary  
 for capacity, 311–14  
 status, outcome, and  
 functional approaches  
 to, 309–11  
 test of capacity, 314–15  
 background on, 306  
*Heart of England NHS  
 Foundation Trust v JB*  
 [2014], 306–7  
 House of Lords report  
 and Supreme Court  
 judgment, 308  
*PC & NC v City of York  
 Council* [2013], 307–8  
 importance of, 305  
 Responsible Bodies (RBs),  
 in LPS, 300  
 responsible clinician (RC),  
 286, 288  
 responsible medical  
 officer (RMO), 286, 288  
 resuscitation, in advanced  
 dementia, 235  
 retina, amyloid- $\beta$  detection  
 in, 165  
 retirement from driving, 141  
 available alternative  
 transport impact  
 on, 142  
 behaviour modification, 141  
 cessation, 142  
 REVEAL project. *See* Risk  
 Evaluation and  
 Education  
 for Alzheimer's  
 Disease project  
 RFP. *See* recovery-focussed  
 practice  
 riluzole, 52  
 Risk Evaluation and Education  
 for Alzheimer's Disease  
 (REVEAL) project, 168  
 risk management,  
 transformation  
 to safety planning,  
 209–10  
 risperidone, 86, 246–7  
 rivastigmine  
 for apathy, 119  
 for PD psychosis, 121  
 for PDD, 122  
 for VaD/VCI, 31–3  
 for young-onset  
 dementia, 46–7  
 RMO. *See* responsible  
 medical officer  
 Rookwood Driving  
 Battery (RDB), 146  
 ropinirole, 118  
 Royal College of General  
 Practitioners, Mental  
 Health Toolkit, 266  
 Royal College of Psychiatrists  
 report on substance misuse  
 and older people, 92  
 young-onset dementia  
 recommendations, 48  
 RR. *See* relative risk  
 SADQ. *See* Severity of  
 Alcohol Dependence  
 Questionnaire  
 SAFE DRIVE checklist, 145  
 safety planning, risk  
 management  
 transformation  
 to, 209–10  
 Sandhoff disease, 68  
 schizophrenia, 14  
 Scotland  
 civil detention in,  
 282–6, 288–90  
 consent to treatment  
 provisions in,  
 286–8, 289  
 mental health laws  
 of, 279–82, 290–1  
 screening instruments,  
 mania in late life, 83  
 SEA. *See* situated  
 embodied agent  
 second opinion safeguards,  
 for compulsory mental  
 health treatment, 287  
 secondary mania, 79–80  
 sedative misuse, 106–7, 108  
 treatment and  
 outcomes of, 113  
 selective serotonin reuptake  
 inhibitors (SSRIs)  
 for depression in PD, 118  
 for late-life depression, 245  
 mania induced by, 79  
 toxicity associated with, 61  
 for young-onset  
 dementia, 47  
 self-harm, 98  
 self-management in  
 dementia, 191, 199  
 adaptation of tools for,  
 196–7  
 concerns and limitations  
 of, 198–9  
 empowerment of, 208–9  
 'living well' concept  
 and, 191–2  
 recovery concept  
 and, 192–3  
 support of, 194–6  
 value and benefits of, 193–4  
 self-reports, assessment  
 of driving risk with, 140  
 semantic dementia, 45  
 sensory interventions,  
 for dementia  
 animal-assisted therapy,  
 216  
 aromatherapy, 215–16  
 light therapy, 215  
 multisensory  
 stimulation, 216  
 Serial Trial Intervention  
 (STI), 232–3  
 sertraline, for late-life  
 depression, 245,  
 246–7, 249  
 Severity of Alcohol  
 Dependence  
 Questionnaire  
 (SADQ), 96–7  
 shared decision-making, 207

- Short Michigan Alcoholism Screening Test – Geriatric version (SMAST-G), 94
- short-term detention, 283–6
- short-term integrated palliative and supportive care (SIPS) model, 229
- Shy–Drager syndrome, 51–2
- single-photon emission computed tomography (SPECT), 173–4
- AD, 177
- DLB, 182–3
- other neuroimaging techniques compared with, 175
- VaD/VCI, 179–80
- SIPS model. *See* short-term integrated palliative and supportive care model
- situated embodied agent (SEA), view of person as, 318–20
- case vignette, 320–4
- discussion, 324–5
- interventions and, 323–4
- therapeutic engagement and, 324
- understanding of patients through, 321–2
- Sjögren syndrome, 71
- small vessel disease (SVD), VaD/VCI after, 27–30, 53
- SMAST-G. *See* Short Michigan Alcoholism Screening Test – Geriatric version
- soccer, dementia and, 63
- Social Care Institute for Excellence, young-onset dementia recommendations, 48
- social care settings, DoL ‘acid test’ in, 298
- social exclusion, in dementia, 205–6
- soluble platelet-derived growth factor receptor  $\beta$  (sPDGFR $\beta$ ), 164
- SPECT. *See* single-photon emission computed tomography
- spinocerebellar ataxias, 52
- spiritual needs, in advanced dementia, 235–6
- sporadic CJD, 54
- SSCS model. *See* Stress-Strain-Coping-Support model
- SSRIs. *See* selective serotonin reuptake inhibitors
- statins, for VaD/VCI, 33
- steroids, toxicity associated with, 61
- STI. *See* Serial Trial Intervention
- stimulant misuse, 108
- Stress-Strain-Coping-Support (SSCS) model, 94–5
- stroke, VaD/VCI after, 26–7, 28
- subacute sclerosing panencephalitis, 58
- subdural haematoma, 64
- substance misuse. *See also* alcohol misuse; drug misuse
- bipolar disorder comorbidity with, 83
- epidemiology of, 16, 92–3, 106, 107
- mental illness with, 110–11
- toxicity associated with, 62
- suicide
- alcohol misuse and, 98
- bipolar disorder and, 81
- epidemiology of, 16, 17, 18
- Supreme Court Judgment in P and Q and P in Cheshire West, 294–6
- residence capacity and, 308
- SVD. *See* small vessel disease
- Sydney Multicenter Study, 122
- syphilis, 56–7
- systemic lupus erythematosus, 71
- systemic vasculitis, 70
- tau proteins, in AD
- at different disease stages, 166
- measurement of, 164–5
- pathophysiology, 162–3
- predictive accuracy of, 165–6
- Taylor, Charles, 319
- Tay–Sachs disease, 68
- TCAs. *See* tricyclic antidepressants
- telephone contact, for home assessment, 131
- therapeutic engagement, 324
- thiamine deficiency, 97
- thyroxine, high levels of, 64
- TMS. *See* transcranial magnetic stimulation
- total tau (t-tau), in AD, 164, 165–6
- toxicity, dementia caused by, 59
- alcohol and recreational drugs, 62
- heavy metals, 58–60
- medications, 60–1
- organophosphates and pesticides, 60
- toxocariasis, 57
- training, dementia care, 267–9
- tranquilliser misuse, 106–7, 108
- transcranial magnetic stimulation (TMS), for late-life depression, 249
- treatment without consent, 286–7
- tribunals, for discharge from civil detention, 288–90
- tricyclic antidepressants (TCAs)
- for depression in PD, 118
- for late-life depression, 246
- mania induced by, 79
- toxicity associated with, 61
- t-tau. *See* total tau
- tube feeding, in advanced dementia, 234
- United Kingdom mental health laws. *See* mental health laws
- United Nations Convention on the Rights of Persons with Disabilities (CRPD), 281, 282, 286, 310
- urgent treatment, compulsory, 287–8
- VaD/VCI. *See* vascular dementia/vascular cognitive impairment

- valproate, 85–6  
 variant CJD (vCJD), 55, 184  
 vascular dementia/vascular cognitive impairment (VaD/VCI), 24–6, 33–4  
   AD compared with, 30–1  
   AD mixed with, 24–5, 26  
   clinical assessment of, 31, 32  
   diagnostic criteria for, 30–1, 178, 179  
   epidemiology of, 10–11, 24–5, 31  
   neuroimaging in  
     diagnosis of, 26–9, 32, 178, 179, 187  
     functional, 179–80  
     periventricular white matter lesions, 179  
 pathology, 25–6  
   CAA, 29, 53  
   diffuse subcortical SVD, 27–30, 53  
   lacunar stroke, 27, 28  
   major stroke, 26–7  
   mechanism  
     underlying, 29–30  
   microinfarcts, 27  
   mixed or multiple forms of, 24–5, 26, 29  
   neuroradiology  
     and, 26–9, 32  
   rare causes of, 53–4  
   treatment of  
     cognitive changes, 31–3  
     control of vascular risk factors, 33  
     symptomatic, 33  
   young-onset, 43  
 vascular depression, 250  
 vascular mania, 80  
 vasculitis, 70  
 vCJD. *See* variant CJD  
 venlafaxine  
   for late-life depression, 245, 246–7  
   mania induced by, 79  
 viral encephalitis, 57  
 vitamin deficiency  
   dementia caused by, 59  
     B<sub>12</sub>, 62–3  
     folate, 62  
     niacin, 62  
   Wernicke's encephalopathy, 97  
 vortioxetine, 246  
 Wellness Recovery Action Plan® (WRAP®), 196–7, 208–9  
 Wernicke's encephalopathy, 97  
*Which?*, care home  
   articles of, 266  
 white matter hyperintensities (WMH), 28–9  
 WHO. *See* World Health Organization  
 Wilson's disease, 66–7  
 withdrawal  
   alcohol, 96–7  
   dopamine agonist, 123  
 Wittgenstein, Ludwig, 320  
 WMH. *See* white matter hyperintensities  
 World Health Organization (WHO), palliative care definition of, 223  
 WRAP®. *See* Wellness Recovery Action Plan®  
 young-onset dementias  
   causes of, 43  
     AD, 43  
     alcohol-related dementia, 45  
     DLB, 45  
     FTDs, 43–5  
     Huntington's and other rarer causes, 45–6  
     VaD/VCI, 43  
   definition of, 38  
   dementias in later life in later life compared with, 38–9  
   diagnosis of  
     clinical approach to assessment for, 40  
     cognitive testing, 41, 42  
     differential, 40  
     distribution of, 39–40  
     further investigations, 41–2  
     history, 40  
     physical examination, 41  
   management of, 46  
   pharmacological interventions, 46–7  
   psychological and non-pharmacological interventions, 47  
   national recommendations for, 48  
   neuroimaging in, 41–2, 185–6  
   prevalence of, 39  
   services for, 38, 47–8  
 ziprasidone, 261–2  
 Zopiclone, 106